$54.47
0.35% today
NYSE, Dec 24, 04:15 pm CET
ISIN
US1101221083
Symbol
BMY

Bristol-Myers Squibb Stock price

$54.28
+6.52 13.65% 1M
+7.36 15.69% 6M
-2.28 4.03% YTD
-3.30 5.73% 1Y
-18.61 25.53% 3Y
-6.72 11.02% 5Y
-14.71 21.32% 10Y
+31.34 136.62% 20Y
NYSE, Closing price Tue, Dec 23 2025
-0.38 0.70%

New AI Insights on Bristol-Myers Squibb Insights AI Insights on Bristol-Myers Squibb

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$110.5b
Enterprise Value
$143.0b
Net debt
$32.5b
Cash
$16.5b
Shares outstanding
2.0b
Valuation (TTM | estimate)
P/E
18.3 | 8.2
P/S
2.3 | 2.3
EV/Sales
3.0 | 3.0
EV/FCF
9.3
P/B
6.0
Dividends
DPS
$2.49
Yield 1Y | 5Y
4.6% | 3.8%
Growth 1Y | 5Y
2.9% | 6.2%
Payout 1Y | 3Y
-54.9% | 288.3%
Increased
19 Years
Financials (TTM | estimate)
Revenue
$48.0b | $48.4b
EBITDA
$20.3b | $17.4b
EBIT
$16.1b | $15.9b
Net Income
$6.0b | $13.5b
Free Cash Flow
$15.3b
Growth (TTM | estimate)
Revenue
1.3% | 0.2%
EBITDA
-1.5% | -14.6%
EBIT
44.7% | 38.1%
Net Income
183.2% | 250.3%
Free Cash Flow
10.9%
Margin (TTM | estimate)
Gross
73.2%
EBITDA
42.2% | 36.0%
EBIT
33.5%
Net
12.6% | 27.8%
Free Cash Flow
31.9%
Financial Health
Equity Ratio
17.6%
Return on Equity
-54.8%
ROCE
23.4%
ROIC
16.9%
Debt/Equity
2.6
More
EPS
$3.0
FCF per Share
$7.5
Short interest
1.7%
Employees
34k
Rev per Employee
$1.4m
Show more

Is Bristol-Myers Squibb a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,085 stocks worldwide.

Bristol-Myers Squibb Stock Analysis

Unlock Scores for Free

Analyst Opinions

34 Analysts have issued a Bristol-Myers Squibb forecast:

11x Buy
32%
21x Hold
62%
2x Sell
6%

Analyst Opinions

34 Analysts have issued a Bristol-Myers Squibb forecast:

Buy
32%
Hold
62%
Sell
6%

Financial data from Bristol-Myers Squibb

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
48,034 48,034
1% 1%
100%
- Direct Costs 12,898 12,898
13% 13%
27%
35,136 35,136
2% 2%
73%
- Selling and Administrative Expenses 7,167 7,167
10% 10%
15%
- Research and Development Expense 9,719 9,719
3% 3%
20%
20,280 20,280
1% 1%
42%
- Depreciation and Amortization 4,184 4,184
56% 56%
9%
EBIT (Operating Income) EBIT 16,096 16,096
45% 45%
34%
Net Profit 6,039 6,039
183% 183%
13%

In millions USD.

Don't miss a Thing! We will send you all news about Bristol-Myers Squibb directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bristol-Myers Squibb Stock News

Neutral
Seeking Alpha
about one hour ago
BMY remains a great Buy, supported by the the deeply discounted valuations, the robust cash flows, the healthier balance sheet, and the secure/richer dividend yields. The Growth Portfolio now drives 56.5% of revenues, temporarily offsetting legacy declines while lending credibility to the thrice raised FY2025 guidance. Otherwise, BMY faces numerous Patent cliffs for Opdivo/Eliquis and the Medic...
Positive
Seeking Alpha
about 9 hours ago
Bristol Myers Squibb remains significantly undervalued, trading at a forward P/E of 8x, versus the sector median of 19.5x. BMY's growth portfolio now generates 57% of total revenue, growing 18% YoY and overtaking legacy drugs, supporting a bullish outlook. Despite modest 3% total revenue growth, BMY maintains robust margins, strong cash flow, and a 4.65% dividend yield, enhancing its defensive ...
Positive
Seeking Alpha
about 23 hours ago
Bristol-Myers Squibb Company has rebounded solidly, as the market finally recognizes prior pessimism was excessive, driving renewed investor interest. Despite an estimated >60% revenue facing loss of exclusivity risks, BMY's growth portfolio delivered 18% growth in Q3 and now exceeds 50% of business mix. Robust free cash flow margins (>30%) and a 4.7% yield provide BMY investors with attractive...
More Bristol-Myers Squibb News

Company Profile

Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The firm offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Head office United States
CEO Christopher Boerner
Employees 34,100
Founded 1933
Website www.bms.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today